A recent transcriptomic analysis of patient-derived xenografts showed that FST is upregulated in ovarian tumors resistant to combination chemotherapy with immune checkpoint inhibitors, whereas the genetic ablation of FST restored drug susceptibility and improved the overall survival of mice with these tumors [84]. This evidence concerns the gene FST and ovarian neoplasm.